For More Posts Like These, Go To @mypsychology​

End of fillings in sight as scientists find Alzheimer's drug makes teeth grow back

Fillings could be consigned to history after scientists discovered that a drug already trialled in Alzheimer's patients can encourage tooth regrowth and repair cavities.

Researchers at King’s College London found that the drug Tideglusib stimulates the stem cells contained in the pulp of teeth so that they generate new dentine – the mineralised material under the enamel.

Teeth already have the capability of regenerating dentine if the pulp inside the tooth becomes exposed through a trauma or infection, but can only naturally make a very thin layer, and not enough to fill the deep cavities caused by tooth decay.

But Tideglusib switches off an enzyme called GSK-3 which prevents dentine from carrying on forming.

Scientists showed it is possible to soak a small biodegradable sponge with the drug and insert it into a cavity, where it triggers the growth of dentine and repairs the damage within six weeks.

The tiny sponges are made out of collagen so they melt away over time, leaving only the repaired tooth.

Is this the whole thing??? It’s the first time I’ve seen this version.

Ye

Yes, that’s the whole image

Back in the 1960s, the U.S. started vaccinating kids for measles. As expected, children stopped getting measles.

But something else happened.

Childhood deaths from all infectious diseases plummeted. Even deaths from diseases like pneumonia and diarrhea were cut by half.

“So it’s really been a mystery — why do children stop dying at such high rates from all these different infections following introduction of the measles vaccine,” says Michael Mina, a postdoc in biology at Princeton University and a medical student at Emory University.

Scientists Crack A 50-Year-Old Mystery About The Measles Vaccine Photo credit: Photofusion/UIG via Getty Images

Better late than never!

Here’s a comic about Cosmic Strings!

https://www.space.com/9315-cracks-universe-physicists-search-cosmic-strings.html

https://www.sciencedaily.com/releases/2008/01/080120182315.htm

Buttless Wonder: New Worm Has No Anus

A strange, new marine worm found on the seafloor of the western Pacific Ocean lacks a number of internal features common to other animals, such as a centralized nervous system, kidneys and an anus.

A bizarre new species of marine worm lacks a number of internal features common to other animals — including an anus, new research shows.

The Hubble Space telescope just sent back a new photo of the Twin Jet Nebula. Here’s what it looked like in 1997:

And now …

Whoa. But wait, we also got an updated image of the merging galaxies NGC 6240. What it looked like in 2008:

And today:

Science, you’re the best. Oh, and the explanation behind those merging galaxies and their black holes is wild.

Antarctic sponges live on a time scale we can barely comprehend. 

Scientists just figured out why poison ivy makes us itch so much

Leaves of three, let them be.

An international team of researchers has finally decoded the science behind a plant responsible for no small degree of human misery: poison ivy.

For the first time, we now know why poison ivy leaves – the bane of campers, hikers, and overly curious kids alike – make us itch, and the answer lies in a key molecule called CD1a, which scientists have long known about but didn’t fully understand until now.

“For over 35 years we have known CD1a is abundant in the skin,” says researcher Jerome Le Nours from Monash University in Australia. “Its role in inflammatory skin disorders has been difficult to investigate and until now has been really unclear.”

One of the reasons for that lack of clarity has been that many experiments on skin disorders involve animal testing – specifically lab mice. And mice don’t produce CD1a, effectively creating a kind of ‘blind spot’ in the studies up to this point.

To get around this and examine whether CD1a might play a part in how human skin reacts when we brush up against poison ivy (Toxicodendron radicans) and similar rash-inducing plants, the researchers genetically engineered mice that did produce the molecule.

In doing so, the team found that CD1a – a protein that plays an important role in our immune systems – triggers a skin-based allergic reaction when we come into contact with urushiol, the allergen that functions as the active ingredient in plants like poison ivy, poison oak, and poison sumac.

When urushiol interacts with skin cells called Langerhans cells, the CD1a proteins (which are expressed by Langerhans cells) activate the immune system’s T cells. In turn, the T cells produce two proteins – interleukin 17 and interleukin 22 – which cause inflammation and itchiness.

Continue Reading.

Deconstructing the placebo response: Why does it work in treating depression?

In the past three decades, the power of placebos has gone through the roof in treating major depressive disorder. In clinical trials for treating depression over that period of time, researchers have reported significant increases in patient’s response rates to placebos — the simple sugar pills given to patients who think that it may be actual medication.

New research conducted by UCLA psychiatrists helps explain how placebos can have such a powerful effect on depression.

“In short,” said Andrew Leuchter, the study’s first author and a professor of psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior, “if you think a pill is going to work, it probably will.”

The UCLA researchers examined three forms of treatment. One was supportive care in which a therapist assessed the patient’s risk and symptoms, and provided emotional support and encouragement but refrained from providing solutions to the patient’s issues that might result in specific therapeutic effects. The other two treatments provided the same type of therapy, but patients also received either medication or placebos.

The researchers found that treatment that incorporating either type of pill — real medication or placebo — yielded better outcomes than supportive care alone. Further, the success of the placebo treatment was closely correlated to people’s expectations before they began treatment. Those who believed that medication was likely to help them were much more likely to respond to placebos. Their belief in the effectiveness of medication was not related to the likelihood of benefitting from medication, however.

“Our study indicates that belief in ‘the power of the pill’ uniquely drives the placebo response, while medications are likely to work regardless of patients’ belief in their effectiveness,” Leuchter said.

The study appears in the current online edition of the British Journal of Psychiatry.

At the beginning and end of the study, patients were asked to complete the Hamilton Rating Scale for Depression, giving researchers a quantitative assessment of how their depression levels changed during treatment. Those who received antidepressant medication and supportive care improved an average of 46 percent, patients who received placebos and supportive care improved an average of 36 percent, and those who received supportive care alone improved an average of just 5 percent.

“Interestingly, while we found that medication was more effective than placebo, the difference was modest,” Leuchter said.

The researchers also found that people who received supportive care alone were more likely to discontinue treatment early than those who received pills.

People with major depressive disorder have a persistent low mood, low self-esteem and a loss of pleasure in things they once enjoyed. The disorder can be disabling, and it can affect a person’s family, work or school life, sleeping and eating habits, and overall health.

In the double-blind study, 88 people ages 18 to 65 who had been diagnosed with depression were given eight weeks of treatment. Twenty received supportive care alone, 29 received a placebo with supportive care and 39 received actual medication with supportive care.

The researchers measured the patients’ expectations for how effective they thought medication and general treatment would be, as well as their impressions of the strength of their relationship with the supportive care provider.

“These results suggest a unique role for people’s expectations about their medication in engendering a placebo response,” Leuchter said. “Higher expectations of medication effectiveness predicted an improvement in placebo-treated subjects, and it’s important to note that people’s expectations about how effective a medication may be were already formed before they entered the trial.”

Leuchter said the research indicates that factors such as direct-to-consumer advertising may be shaping peoples’ attitudes about medication. “It may not be an accident that placebo response rates have soared at the same time the pharmaceutical companies are spending $10 billion a year on consumer advertising.”

(Image credit: © Chris Lamphear)